Roles of genetic variants in the PI3K and RAS/RAF pathways in susceptibility to endometrial cancer and clinical outcomes

Journal of Cancer Research and Clinical Oncology

Volumn 138, Issue 3, 2012, Pages 377-385

  Wang, Li E ^a   Ma, Hongxia ^a   Hale, Katherine S ^a   Yin, Ming ^a   Meyer, Larissa A ^a   Liu, Hongliang ^a   Li, Jie ^a   Lu, Karen H ^a   Hennessy, Bryan T ^a   Li, Xuesong ^a   Spitz, Margaret R ^a   Wei, Qingyi ^a   Mills, Gordon B ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Endometrial cancer risk; PI3K PTEN AKT mTOR and RAS RAF MEK ERK pathways; Polymorphisms; Recurrence; Survival

Indexed keywords

MAMMALIAN TARGET OF RAPAMYCIN; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN KINASE B; RAF PROTEIN; RAS PROTEIN; AKT1 PROTEIN, HUMAN; MTOR PROTEIN, HUMAN; PIK3CA PROTEIN, HUMAN; PROTEIN P21; PTEN PROTEIN, HUMAN; TARGET OF RAPAMYCIN KINASE;

ADULT; AKT1 GENE; AKT2 GENE; AKT3 GENE; ARTICLE; BRAF GENE; CANCER RECURRENCE; CANCER RISK; CANCER SURVIVAL; CANCER SUSCEPTIBILITY; CLINICAL ASSESSMENT; CONTROLLED STUDY; ENDOMETRIUM CANCER; FEMALE; FRAP1 GENE; GENE DOSAGE; GENE FUNCTION; GENE INTERACTION; GENE LOCUS; GENETIC ASSOCIATION; GENETIC VARIABILITY; HUMAN; KRAS GENE; MAJOR CLINICAL STUDY; OUTCOME ASSESSMENT; PDPK1 GENE; PIK3CA GENE; PRIORITY JOURNAL; PTEN GENE; RISK ASSESSMENT; RISK REDUCTION; SINGLE NUCLEOTIDE POLYMORPHISM; TUMOR GENE; AGED; CASE CONTROL STUDY; ENDOMETRIUM TUMOR; GENETIC PREDISPOSITION; GENETICS; GENOTYPE; KAPLAN MEIER METHOD; METABOLISM; MIDDLE AGED; MORTALITY; PATHOLOGY; PILOT STUDY; PROPORTIONAL HAZARDS MODEL; RISK; RISK FACTOR; SIGNAL TRANSDUCTION; STATISTICAL MODEL; TREATMENT OUTCOME;

AGED; CASE-CONTROL STUDIES; ENDOMETRIAL NEOPLASMS; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; KAPLAN-MEIER ESTIMATE; LOGISTIC MODELS; MIDDLE AGED; ODDS RATIO; PHOSPHATIDYLINOSITOL 3-KINASES; PILOT PROJECTS; POLYMORPHISM, SINGLE NUCLEOTIDE; PROPORTIONAL HAZARDS MODELS; PROTO-ONCOGENE PROTEINS C-AKT; PROTO-ONCOGENE PROTEINS P21(RAS); PTEN PHOSPHOHYDROLASE; RAF KINASES; RISK ASSESSMENT; RISK FACTORS; SIGNAL TRANSDUCTION; TOR SERINE-THREONINE KINASES; TREATMENT OUTCOME;

EID: 84859698883     PISSN: 01715216     EISSN: 14321335     Source Type: Journal    
DOI: 10.1007/s00432-011-1103-0     Document Type: Article

References (44)

1. Abal M, Planaguma J, Gil-Moreno A, Monge M, Gonzalez M, Baro T, Garcia A, Castellvi J, Ramon YCS, Xercavins J, Alameda F, Reventos J (2006) Molecular pathology of endometrial carcinoma: transcriptional signature in endometrioid tumors. Histol Histopathol 21(2):197-204 (Pubitemid 43033728)
2. Abrams SL, Steelman LS, Shelton JG, Wong EW, Chappell WH, Basecke J, Stivala F, Donia M, Nicoletti F, Libra M, Martelli AM, McCubrey JA (2010) The Raf/MEK/ERK pathway can govern drug resistance, apoptosis and sensitivity to targeted therapy. Cell Cycle 9(9):1781-1791
3. Akhmedkhanov A, Zeleniuch-Jacquotte A, Toniolo P (2001) Role of exogenous and endogenous hormones in endometrial cancer: review of the evidence and research perspectives. Ann N Y Acad Sci 943:296-315 (Pubitemid 32928322)
4. Almind K, Delahaye L, Hansen T, Van Obberghen E, Pedersen O, Kahn CR (2002) Characterization of the Met326Ile variant of phosphatidylinositol 3-kinase p85alpha. Proc Natl Acad Sci USA 99(4):2124-2128 (Pubitemid 34169025)
5. Antico-Arciuch VG, Dima M, Liao XH, Refeto V S, Di Cristofano A (2010) Cross-talk between PI3K and estrogen in the mouse thyroid predisposes to the development of follicular carcinomas with a higher incidence in females. Oncogene
6. Arcaro A, Guerreiro AS (2007) The phosphoinositide 3-kinase pathway in human cancer: genetic alterations and therapeutic implications. Curr Genomics 8(5):271-306 (Pubitemid 351210980)
7. Bellacosa A, Kumar CC, Di Cristofano A, Testa JR (2005) Activation of AKT kinases in cancer: implications for therapeutic targeting. Adv Cancer Res 94:29-86 (Pubitemid 41202364)
8. Carpten JD, Faber AL, Horn C, Donoho GP, Briggs SL, Robbins CM, Hostetter G, Boguslawski S, Moses TY, Savage S, Uhlik M, Lin A, Du J, Qian YW, Zeckner DJ, Tucker-Kellogg G, Touchman J, Patel K, Mousses S, Bittner M, Schevitz R, Lai MH, Blanchard KL, Thomas JE (2007) A transforming mutation in the pleckstrin homology domain of AKT1 in cancer. Nature 448(7152):439-444 (Pubitemid 47123510)
9. Catasus L, Gallardo A, Cuatrecasas M, Prat J (2008) PIK3CA mutations in the kinase domain (exon 20) of uterine endometrial adenocarcinomas are associated with adverse prognostic parameters. Mod Pathol 21(2):131-139 (Pubitemid 351172164)
10. Catasus L, Gallardo A, Cuatrecasas M, Prat J (2009) Concomitant PI3K-AKT and p53 alterations in endometrial carcinomas are associated with poor prognosis. Mod Pathol 22(4):522-529
11. Chen JS, Wang Q, Fu XH, Huang XH, Chen XL, Cao LQ, Chen LZ, Tan HX, Li W, Bi J, Zhang LJ (2009) Involvement of PI3K/ PTEN/AKT/mTOR pathway in invasion and metastasis in hepatocellular carcinoma: association with MMP-9. Hepatol Res 39(2):177-186
12. Hayes MP, Wang H, Espinal-Witter R, Douglas W, Solomon GJ, Baker SJ, Ellenson LH (2006) PIK3CA and PTEN mutations in uterine endometrioid carcinoma and complex atypical hyperplasia. Clin Cancer Res 12(20 Pt 1):5932-5935 (Pubitemid 44703751)
13. Hildebrandt MA, Yang H, Hung MC, Izzo JG, Huang M, Lin J, Ajani JA, Wu X (2009) Genetic variations in the PI3K/PTEN/AKT/ mTOR pathway are associated with clinical outcomes in esophageal cancer patients treated with chemoradiotherapy. J Clin Oncol 27(6):857-871
14. Kirkegaard T, Witton CJ, McGlynn LM, Tovey SM, Dunne B, Lyon A, Bartlett JM (2005) AKT activation predicts outcome in breast cancer patients treated with tamoxifen. J Pathol 207(2):139-146 (Pubitemid 41404144)
15. Konstantinova D, Kaneva R, Dimitrov R, Savov A, Ivanov S, Dyankova T, Kremensky I, Mitev V (2010) Rare mutations in the PIK3CA gene contribute to aggressive endometrial cancer. DNA Cell Biol 29(2):65-70
16. Lacey JV Jr, Yang H, Gaudet MM, Dunning A, Lissowska J, Sherman ME, Peplonska B, Brinton LA, Healey CS, Ahmed S, Pharoah P, Easton D, Chanock S, Garcia-Closas M (2011) Endometrial cancer and genetic variation in PTEN, PIK3CA, AKT1, MLH1, and MSH2 within a population-based case-control study. Gynecol Oncol 120(2):167-173
17. Lax SF (2007) Molecular genetic changes in epithelial, stromal and mixed neoplasms of the endometrium. Pathology 39(1):46-54
18. Li J, Yen C, Liaw D, Podsypanina K, Bose S, Wang SI, Puc J, Miliaresis C, Rodgers L, McCombie R, Bigner SH, Giovanella BC, Ittmann M, Tycko B, Hibshoosh H, Wigler MH, Parsons R (1997) PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer. Science 275(5308): 1943-1947 (Pubitemid 27148818)
19. Li L, Plummer SJ, Thompson CL, Tucker TC, Casey G (2008) Association between phosphatidylinositol 3-kinase regulatory subunit p85alpha Met326Ile genetic polymorphism and colon cancer risk. Clin Cancer Res 14(3):633-637 (Pubitemid 351231141)
20. Luo J, Cantley LC (2005) The negative regulation of phosphoinositide 3-kinase signaling by p85 and it's implication in cancer. Cell Cycle 4(10):1309-1312 (Pubitemid 41437108)
21. Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW, Harris PL, Haserlat SM, Supko JG, Haluska FG, Louis DN, Christiani DC, Settleman J, Haber DA (2004) Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 350(21):2129-2139 (Pubitemid 38637993)
22. Manning BD, Cantley LC (2007) AKT/PKB signaling: navigating downstream. Cell 129(7):1261-1274 (Pubitemid 46962095)
23. McCubrey JA, Steelman LS, Abrams SL, Lee JT, Chang F, Bertrand FE, Navolanic PM, Terrian DM, Franklin RA, D'Assoro AB, Salisbury JL, Mazzarino MC, Stivala F, Libra M (2006) Roles of the RAF/MEK/ERK and PI3K/PTEN/AKT pathways in malignant transformation and drug resistance. Adv Enzyme Regul 46:249-279 (Pubitemid 44301348)
24. Minaguchi T, Yoshikawa H, Oda K, Ishino T, Yasugi T, Onda T, Nakagawa S, Matsumoto K, Kawana K, Taketani Y (2001) PTEN mutation located only outside exons 5, 6, and 7 is an independent predictor of favorable survival in endometrial carcinomas. Clin Cancer Res 7(9):2636-2642 (Pubitemid 32911365)
25. Mizuuchi H, Nasim S, Kudo R, Silverberg SG, Greenhouse S, Garrett CT (1992) Clinical implications of K-ras mutations in malignant epithelial tumors of the endometrium. Cancer Res 52(10):2777-2781
26. Mori N, Kyo S, Sakaguchi J, Mizumoto Y, Ohno S, Maida Y, Hashimoto M, Takakura M, Inoue M (2007) Concomitant activation of AKT with extracellular-regulated kinase 1/2 occurs independently of PTEN or PIK3CA mutations in endometrial cancer and may be associated with favorable prognosiss. Cancer Sci 98(12):1881-1888 (Pubitemid 350002193)
27. Murayama-Hosokawa S, Oda K, Nakagawa S, Ishikawa S, Yamamoto S, Shoji K, Ikeda Y, Uehara Y, Fukayama M, McCormick F, Yano T, Taketani Y, Aburatani H (2010) Genome-wide singlenucleotide polymorphism arrays in endometrial carcinomas associate extensive chromosomal instability with poor prognosis and unveil frequent chromosomal imbalances involved in the PI3-kinase pathway. Oncogene 29(13):1897-1908
28. Nicholson KM, Anderson NG (2002) The protein kinase B/Akt signalling pathway in human malignancy. Cell Signal 14(5):381-395 (Pubitemid 34214843)
29. Ninomiya Y, Kato K, Takahashi A, Ueoka Y, Kamikihara T, Arima T, Matsuda T, Kato H, Nishida J, Wake N (2004) K-Ras and H-Ras activation promote distinct consequences on endometrial cell survival. Cancer Res 64(8):2759-2765 (Pubitemid 38500613)
30. Oehler MK, Brand A, Wain GV (2003) Molecular genetics and endometrial cancer. J Br Menopause Soc 9(1):27-31 (Pubitemid 36362090)
31. Paynter RA, Hankinson SE, Colditz GA, Kraft P, Hunter DJ, De Vivo I (2005) CYP19 (aromatase) haplotypes and endometrial cancer risk. Int J Cancer 116(2):267-274 (Pubitemid 40967264)
32. Philp AJ, Campbell IG, Leet C, Vincan E, Rockman SP, Whitehead RH, Thomas RJ, Phillips WA (2001) The phosphatidylinositol 3- kinase p85alpha gene is an oncogene in human ovarian and colon tumors. Cancer Res 61(20):7426-7429
33. Pu X, Hildebrandt MA, Lu C, Lin J, Stewart DJ, Ye Y, Gu J, Spitz MR, Wu X (2010) PI3K/PTEN/AKT/mTOR pathway genetic variation predicts toxicity and distant progression in lung cancer patients receiving platinum-based chemotherapy. Lung Cancer
34. Quaye L, Song H, Ramus SJ, Gentry-Maharaj A, Hogdall E, Di Cioccio RA, McGuire V, Wu AH, Van Den Berg DJ, Pike MC, Wozniak E, Doherty JA, Rossing MA, Ness RB, Moysich KB, Hogdall C, Blaakaer J, Easton DF, Ponder BA, Jacobs IJ, Menon U, Whittemore AS, Kruger-Kjaer S, Pearce CL, Pharoah PD, Gayther SA (2009) Tagging single-nucleotide polymorphisms in candidate oncogenes and susceptibility to ovarian cancer. Br J Cancer 100(6):993-1001
35. Rudd ML, Price JC, Fogoros S, Godwin AK, Sgroi DC, Merino MJ, Bell DW (2011) A unique spectrum of somatic PIK3CA (p110{alpha}) mutations within primary endometrial carcinomas. Clin Cancer Res 17(6):1331-1340
36. Samuels Y, Wang Z, Bardelli A, Silliman N, Ptak J, Szabo S, Yan H, Gazdar A, Powell SM, Riggins GJ, Willson JK, Markowitz S, Kinzler KW, Vogelstein B, Velculescu VE (2004) High frequency of mutations of the PIK3CA gene in human cancers. Science 304(5670):554 (Pubitemid 38541907)
37. Siegel R, Ward E, Brawley O, Jemal A (2011) Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin 61(4):212-236
38. Steelman LS, Stadelman KM, Chappell WH, Horn S, Basecke J, Cervello M, Nicoletti F, Libra M, Stivala F, Martelli AM, McCubrey JA (2008) Akt as a therapeutic target in cancer. Expert Opin Ther Targets 12(9):1139-1165
39. Steelman LS, Abrams SL, Shelton JG, Chappell WH, Basecke J, Stivala F, Donia M, Nicoletti F, Libra M, Martelli AM, McCubrey JA (2010) Dominant roles of the Raf/MEK/ERK pathway in cell cycle progression, prevention of apoptosis and sensitivity to chemotherapeutic drugs. Cell Cycle 9:8
40. Testa JR, Bellacosa A (2001) AKT plays a central role in tumorigenesis. Proc Natl Acad Sci USA 98(20):10983-10985 (Pubitemid 32928669)
41. Treloar SA, Zhao ZZ, Le L, Zondervan KT, Martin NG, Kennedy S, Nyholt DR, Montgomery GW (2007) Variants in EMX2 and PTEN do not contribute to risk of endometriosis. Mol Hum Reprod 13(8):587-594 (Pubitemid 47241912)
42. Urick ME, Rudd ML, Godwin AK, Sgroi DC, Merino M, Bell DW (2011) PIK3R1 (p85-alpha/p85{alpha}) is somatically mutated at high frequency in primary endometrial cancer. Cancer Res
43. Wang T, Ho G, Ye K, Strickler H, Elston RC (2009) A partial leastsquare approach for modeling gene-gene and gene-environment interactions when multiple markers are genotyped. Genet Epidemiol 33(1):6-15
44. Yuan TL, Cantley LC (2008) PI3K pathway alterations in cancer: variations on a theme. Oncogene 27(41):5497-5510